The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-GFP Antibody Market Research Report 2025

Global Anti-GFP Antibody Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1897605

No of Pages : 107

Ask Your Query
Synopsis
Anti-GFP Antibody refers to an antibody that specifically recognizes and binds to green fluorescent protein (GFP). GFP is a naturally occurring protein that emits green fluorescence when exposed to light in the blue to UV range. It is widely used as a reporter molecule in molecular biology and cell biology research to visualize protein expression and localization in vivo. The Anti-GFP Antibody is used to detect and quantify GFP-tagged proteins in various experimental settings, including western blotting, immunofluorescence, and immunohistochemistry.
The global Anti-GFP Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The industry trend for Anti-GFP Antibody has experienced significant growth due to the increasing use of GFP in genetic engineering, cell tracking, and fluorescence microscopy. The antibody is essential for researchers to validate the successful expression and functionality of GFP-tagged fusion proteins in their experimental systems. Furthermore, the development of more sensitive and specific Anti-GFP Antibodies, as well as the expansion of applications such as live-cell imaging and protein-protein interaction studies, is driving the demand for this product. As the field of fluorescent protein technology continues to advance, the industry trend for Anti-GFP Antibody is expected to remain strong.
This report aims to provide a comprehensive presentation of the global market for Anti-GFP Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-GFP Antibody.
Report Scope
The Anti-GFP Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-GFP Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-GFP Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
FUJIFILM Wako Chemicals
ProSci
GeneTex
Bioss
Rockland Immunochemicals
Cell Signaling Technology
Novus Biologicals
Thermo Fisher Scientific
Biorbyt
R&D Systems
BioLegend
OriGene Technologies
ImmuQuest
Abbexa
EpiGentek
Synaptic Systems
Santa Cruz Biotechnology
Proteintech Group
IBL
LSBio
Signalway Antibody
Agrisera
Bio X Cell
StressMarq Biosciences
RayBiotech
Abnova
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-GFP Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-GFP Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Anti-GFP Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-GFP Antibody Market Perspective (2019-2030)
2.2 Anti-GFP Antibody Growth Trends by Region
2.2.1 Global Anti-GFP Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-GFP Antibody Historic Market Size by Region (2019-2024)
2.2.3 Anti-GFP Antibody Forecasted Market Size by Region (2025-2030)
2.3 Anti-GFP Antibody Market Dynamics
2.3.1 Anti-GFP Antibody Industry Trends
2.3.2 Anti-GFP Antibody Market Drivers
2.3.3 Anti-GFP Antibody Market Challenges
2.3.4 Anti-GFP Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-GFP Antibody Players by Revenue
3.1.1 Global Top Anti-GFP Antibody Players by Revenue (2019-2024)
3.1.2 Global Anti-GFP Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Anti-GFP Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-GFP Antibody Revenue
3.4 Global Anti-GFP Antibody Market Concentration Ratio
3.4.1 Global Anti-GFP Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-GFP Antibody Revenue in 2023
3.5 Anti-GFP Antibody Key Players Head office and Area Served
3.6 Key Players Anti-GFP Antibody Product Solution and Service
3.7 Date of Enter into Anti-GFP Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-GFP Antibody Breakdown Data by Type
4.1 Global Anti-GFP Antibody Historic Market Size by Type (2019-2024)
4.2 Global Anti-GFP Antibody Forecasted Market Size by Type (2025-2030)
5 Anti-GFP Antibody Breakdown Data by Application
5.1 Global Anti-GFP Antibody Historic Market Size by Application (2019-2024)
5.2 Global Anti-GFP Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-GFP Antibody Market Size (2019-2030)
6.2 North America Anti-GFP Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-GFP Antibody Market Size by Country (2019-2024)
6.4 North America Anti-GFP Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-GFP Antibody Market Size (2019-2030)
7.2 Europe Anti-GFP Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-GFP Antibody Market Size by Country (2019-2024)
7.4 Europe Anti-GFP Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-GFP Antibody Market Size (2019-2030)
8.2 Asia-Pacific Anti-GFP Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-GFP Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-GFP Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-GFP Antibody Market Size (2019-2030)
9.2 Latin America Anti-GFP Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-GFP Antibody Market Size by Country (2019-2024)
9.4 Latin America Anti-GFP Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-GFP Antibody Market Size (2019-2030)
10.2 Middle East & Africa Anti-GFP Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-GFP Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-GFP Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 FUJIFILM Wako Chemicals
11.1.1 FUJIFILM Wako Chemicals Company Detail
11.1.2 FUJIFILM Wako Chemicals Business Overview
11.1.3 FUJIFILM Wako Chemicals Anti-GFP Antibody Introduction
11.1.4 FUJIFILM Wako Chemicals Revenue in Anti-GFP Antibody Business (2019-2024)
11.1.5 FUJIFILM Wako Chemicals Recent Development
11.2 ProSci
11.2.1 ProSci Company Detail
11.2.2 ProSci Business Overview
11.2.3 ProSci Anti-GFP Antibody Introduction
11.2.4 ProSci Revenue in Anti-GFP Antibody Business (2019-2024)
11.2.5 ProSci Recent Development
11.3 GeneTex
11.3.1 GeneTex Company Detail
11.3.2 GeneTex Business Overview
11.3.3 GeneTex Anti-GFP Antibody Introduction
11.3.4 GeneTex Revenue in Anti-GFP Antibody Business (2019-2024)
11.3.5 GeneTex Recent Development
11.4 Bioss
11.4.1 Bioss Company Detail
11.4.2 Bioss Business Overview
11.4.3 Bioss Anti-GFP Antibody Introduction
11.4.4 Bioss Revenue in Anti-GFP Antibody Business (2019-2024)
11.4.5 Bioss Recent Development
11.5 Rockland Immunochemicals
11.5.1 Rockland Immunochemicals Company Detail
11.5.2 Rockland Immunochemicals Business Overview
11.5.3 Rockland Immunochemicals Anti-GFP Antibody Introduction
11.5.4 Rockland Immunochemicals Revenue in Anti-GFP Antibody Business (2019-2024)
11.5.5 Rockland Immunochemicals Recent Development
11.6 Cell Signaling Technology
11.6.1 Cell Signaling Technology Company Detail
11.6.2 Cell Signaling Technology Business Overview
11.6.3 Cell Signaling Technology Anti-GFP Antibody Introduction
11.6.4 Cell Signaling Technology Revenue in Anti-GFP Antibody Business (2019-2024)
11.6.5 Cell Signaling Technology Recent Development
11.7 Novus Biologicals
11.7.1 Novus Biologicals Company Detail
11.7.2 Novus Biologicals Business Overview
11.7.3 Novus Biologicals Anti-GFP Antibody Introduction
11.7.4 Novus Biologicals Revenue in Anti-GFP Antibody Business (2019-2024)
11.7.5 Novus Biologicals Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Anti-GFP Antibody Introduction
11.8.4 Thermo Fisher Scientific Revenue in Anti-GFP Antibody Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Biorbyt
11.9.1 Biorbyt Company Detail
11.9.2 Biorbyt Business Overview
11.9.3 Biorbyt Anti-GFP Antibody Introduction
11.9.4 Biorbyt Revenue in Anti-GFP Antibody Business (2019-2024)
11.9.5 Biorbyt Recent Development
11.10 R&D Systems
11.10.1 R&D Systems Company Detail
11.10.2 R&D Systems Business Overview
11.10.3 R&D Systems Anti-GFP Antibody Introduction
11.10.4 R&D Systems Revenue in Anti-GFP Antibody Business (2019-2024)
11.10.5 R&D Systems Recent Development
11.11 BioLegend
11.11.1 BioLegend Company Detail
11.11.2 BioLegend Business Overview
11.11.3 BioLegend Anti-GFP Antibody Introduction
11.11.4 BioLegend Revenue in Anti-GFP Antibody Business (2019-2024)
11.11.5 BioLegend Recent Development
11.12 OriGene Technologies
11.12.1 OriGene Technologies Company Detail
11.12.2 OriGene Technologies Business Overview
11.12.3 OriGene Technologies Anti-GFP Antibody Introduction
11.12.4 OriGene Technologies Revenue in Anti-GFP Antibody Business (2019-2024)
11.12.5 OriGene Technologies Recent Development
11.13 ImmuQuest
11.13.1 ImmuQuest Company Detail
11.13.2 ImmuQuest Business Overview
11.13.3 ImmuQuest Anti-GFP Antibody Introduction
11.13.4 ImmuQuest Revenue in Anti-GFP Antibody Business (2019-2024)
11.13.5 ImmuQuest Recent Development
11.14 Abbexa
11.14.1 Abbexa Company Detail
11.14.2 Abbexa Business Overview
11.14.3 Abbexa Anti-GFP Antibody Introduction
11.14.4 Abbexa Revenue in Anti-GFP Antibody Business (2019-2024)
11.14.5 Abbexa Recent Development
11.15 EpiGentek
11.15.1 EpiGentek Company Detail
11.15.2 EpiGentek Business Overview
11.15.3 EpiGentek Anti-GFP Antibody Introduction
11.15.4 EpiGentek Revenue in Anti-GFP Antibody Business (2019-2024)
11.15.5 EpiGentek Recent Development
11.16 Synaptic Systems
11.16.1 Synaptic Systems Company Detail
11.16.2 Synaptic Systems Business Overview
11.16.3 Synaptic Systems Anti-GFP Antibody Introduction
11.16.4 Synaptic Systems Revenue in Anti-GFP Antibody Business (2019-2024)
11.16.5 Synaptic Systems Recent Development
11.17 Santa Cruz Biotechnology
11.17.1 Santa Cruz Biotechnology Company Detail
11.17.2 Santa Cruz Biotechnology Business Overview
11.17.3 Santa Cruz Biotechnology Anti-GFP Antibody Introduction
11.17.4 Santa Cruz Biotechnology Revenue in Anti-GFP Antibody Business (2019-2024)
11.17.5 Santa Cruz Biotechnology Recent Development
11.18 Proteintech Group
11.18.1 Proteintech Group Company Detail
11.18.2 Proteintech Group Business Overview
11.18.3 Proteintech Group Anti-GFP Antibody Introduction
11.18.4 Proteintech Group Revenue in Anti-GFP Antibody Business (2019-2024)
11.18.5 Proteintech Group Recent Development
11.19 IBL
11.19.1 IBL Company Detail
11.19.2 IBL Business Overview
11.19.3 IBL Anti-GFP Antibody Introduction
11.19.4 IBL Revenue in Anti-GFP Antibody Business (2019-2024)
11.19.5 IBL Recent Development
11.20 LSBio
11.20.1 LSBio Company Detail
11.20.2 LSBio Business Overview
11.20.3 LSBio Anti-GFP Antibody Introduction
11.20.4 LSBio Revenue in Anti-GFP Antibody Business (2019-2024)
11.20.5 LSBio Recent Development
11.21 Signalway Antibody
11.21.1 Signalway Antibody Company Detail
11.21.2 Signalway Antibody Business Overview
11.21.3 Signalway Antibody Anti-GFP Antibody Introduction
11.21.4 Signalway Antibody Revenue in Anti-GFP Antibody Business (2019-2024)
11.21.5 Signalway Antibody Recent Development
11.22 Agrisera
11.22.1 Agrisera Company Detail
11.22.2 Agrisera Business Overview
11.22.3 Agrisera Anti-GFP Antibody Introduction
11.22.4 Agrisera Revenue in Anti-GFP Antibody Business (2019-2024)
11.22.5 Agrisera Recent Development
11.23 Bio X Cell
11.23.1 Bio X Cell Company Detail
11.23.2 Bio X Cell Business Overview
11.23.3 Bio X Cell Anti-GFP Antibody Introduction
11.23.4 Bio X Cell Revenue in Anti-GFP Antibody Business (2019-2024)
11.23.5 Bio X Cell Recent Development
11.24 StressMarq Biosciences
11.24.1 StressMarq Biosciences Company Detail
11.24.2 StressMarq Biosciences Business Overview
11.24.3 StressMarq Biosciences Anti-GFP Antibody Introduction
11.24.4 StressMarq Biosciences Revenue in Anti-GFP Antibody Business (2019-2024)
11.24.5 StressMarq Biosciences Recent Development
11.25 RayBiotech
11.25.1 RayBiotech Company Detail
11.25.2 RayBiotech Business Overview
11.25.3 RayBiotech Anti-GFP Antibody Introduction
11.25.4 RayBiotech Revenue in Anti-GFP Antibody Business (2019-2024)
11.25.5 RayBiotech Recent Development
11.26 Abnova
11.26.1 Abnova Company Detail
11.26.2 Abnova Business Overview
11.26.3 Abnova Anti-GFP Antibody Introduction
11.26.4 Abnova Revenue in Anti-GFP Antibody Business (2019-2024)
11.26.5 Abnova Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock